We found (Figure 1G) that the HADHA expression had fallen to 73% (95% CI 64%-83%) in subjects with cancer; with a higher expression in ER + subjects (76% of the no cancer group, 95% CI 61%-91%) than in ER-subjects (70% of the no cancer group, 95% CI 55%-85%). Here, HADHA is linked to cancer.